Previous Close | 75.96 |
Open | 76.50 |
Bid | 76.02 x 900 |
Ask | 76.37 x 3000 |
Day's Range | 75.34 - 77.15 |
52 Week Range | 53.22 - 78.47 |
Volume | |
Avg. Volume | 15,535,258 |
Market Cap | 162.213B |
Beta (5Y Monthly) | 0.48 |
PE Ratio (TTM) | 26.99 |
EPS (TTM) | 2.82 |
Earnings Date | Jul 27, 2022 |
Forward Dividend & Yield | 2.16 (2.84%) |
Ex-Dividend Date | Mar 31, 2022 |
1y Target Est | 79.40 |
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.
We have made huge strides in research across lung cancer types, stages and patient groups
PRINCETON, N.J., May 19, 2022--Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders